Stock listing

Frankfurt:Z45 Alvotech Aktie

German listing (Frankfurt) of Alvotech · home listing NASDAQ:ALVO

Follow Alvotech into a list and get an email when it puts out news.

Share price · FWB:Z45

€4.05 EUR +0.05 (+1.2%)

Close on Oct 27, 2026

Day range
€3.87 – €4.05 EUROct 27, 2026
Market cap
€1.45B EURAt the close on Oct 27, 2026 · price × 356.8M shares outstanding
Alvotech logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALVO · Home$4.65 USD-0.24 (-4.9%)714,816$4.85$4.87$4.555$4.89Close on Oct 30, 2026
Frankfurt:Z45€4.05 EUR+0.05 (+1.2%)—€3.97€4.05€3.87€4.00Close on Oct 27, 2026
Ticker
Frankfurt:Z45
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Alvotech (NASDAQ:ALVO) Q3 2026 Earnings Call

    Thu, Nov 12, 2026 · 8:00 AM ET

    Register

Replays

  • Alvotech (NASDAQ:ALVO) Q2 2026 Earnings Call

    Thu, Aug 20, 2026 · 8:00 AM ET

    Watch Transcript

  • Alvotech (NASDAQ:ALVO) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

  • Alvotech (NASDAQ:ALVO) Q4 2025 Earnings Call

    Thu, Mar 19, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Oct 28, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Oct 20, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Oct 14, 2026

Alvotech: Half yearly financial audit reports reviews 2026 10 07 13h09m51 (1)

Oct 12, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Oct 6, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Oct 5, 2026

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

Aug 31, 2026

Alvotech to present at upcoming investor conferences in September

Aug 27, 2026

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Aug 21, 2026

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

Aug 19, 2026

All Alvotech news

Decks

Alvotech on 6ix

Sector
Health care
Industry
Biotechnology
News releases
51 in the last 12 months · 220 in all · newest Oct 28, 2026 · oldest 2022
Calls
17 calls with a replay · 17 with a transcript · latest Aug 20, 2026
Decks
11 decks · latest Aug 20, 2026

Where Alvotech is listed

ListingExchangeCountryCurrency
NASDAQ:ALVO · Home listingNASDAQUnited StatesUSD
OMXICE:ALVOOMXICEIcelandISK
Stockholm:ALVOSDBStockholmSwedenSEK
LS Exchange:A3DK8ULS ExchangeGermanyEUR
Lang & Schwarz:A3DK8ULang & SchwarzGermanyEUR
gettex:Z45gettexGermanyEUR
Frankfurt:Z450FrankfurtGermanyEUR
BX Swiss:ALVOBX SwissSwitzerlandCHF
BOATS:ALVOBOATSUnited StatesUSD
Dusseldorf:Z450DusseldorfGermanyEUR
Frankfurt:Z45 · This pageFrankfurtGermanyEUR
Munich:Z45MunichGermanyEUR
Stuttgart:Z45StuttgartGermanyEUR
BX Swiss:ALVOUSDBX SwissSwitzerlandUSD
Dusseldorf:Z45DusseldorfGermanyEUR
Hamburg:Z45HamburgGermanyEUR
Turquoise:ALVOSTurquoiseUnited KingdomSEK

Log in to ask 6ix AI your own questions about Alvotech.